BSX BOSTON SCIENTIFIC CORPORATION

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Boston Scientific Corporation and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) concerning possible violations of federal securities laws.

If you purchased shares of Boston Scientific, and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].

On February 23, 2017, Boston Scientific announced it would be recalling its range of Lotus Valve heart devices, due to reports of an early release of a pin that connects the heart valve device to the delivery system.

Boston Scientific claims the problem is created by "excess tension in the pin mechanism introduced during the manufacturing process." When this information was released to the investing public, shares of Boston Scientific fell, causing investors harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

EN
23/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BOSTON SCIENTIFIC CORPORATION

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold 14,506 shares at 66.450USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Boston Scientific Corporation: Update to credit analysis following rat...

Our credit view of this issuer reflects its leading position in key markets and its broad product and geographic diversification, against its persistent appetite for acquisitions.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch